Didier Leclercq is the new vice president of global market development at Aerolase. He most recently served as managing director of the Nestlé Skin Health/Galderma SHIELD innovation center in New York City. Prior to managing SHIELD, Leclercq ran Q-Med once it was acquired by Galderma, with the Q-Med portfolio including leading injectables, such as Restylane fillers and Dysport.
“Didier brings a rich array of expertise which will accelerate our path to industry leadership based on our commitment to excellence in laser skin health,” said Pavel Efremkin PhD, chairman and CEO of Aerolase. “His background in aesthetic injectables and pharmaceuticals is an ideal complement to our high innovation position in dermatology lasers, as we incorporate our gold standard devices into powerful combo therapy protocols in concert with toxins, fillers and medications.”
“Over the years I have come to respect Aerolase as a significant innovator and emerging force in the dermatology and aesthetic field. In fact, it was the only laser we saw fit to feature at the SHIELD innovation center,” said Leclercq. “The Aerolase portability combined with top efficacies in multiple key derm treatment areas makes it a unique and powerful device range.”
